Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (...
R. Pinninti, K. Subramaniyan, R. Iyer et al.· Journal of Clinical Medicine· 0 citations
Purpose Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer (EBC) is treated with curative intent, but risk of recurrence (RoR) remains a challenge. The identification of high RoR EBC patients is inconsistent, highlighting the need for a simplified approach. This...
K. Mallavarapu, Rakesh Reddy B, Somashekhar Sp et al.· Breast Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.